1 Interactions were investigated between loreclezole, chlormethiazole and pentobarbitone as potentiators of depolarization responses mediated by g-aminobutyric acid A (GABA A ) receptors on aerent nerve terminals in the rat cuneate nucleus in vitro. These drugs were also compared as modulators of [ 3 H]-¯unitrazepam (FNZ) binding to synaptic membranes prepared from rat whole brain homogenate. 2 In rat cuneate nucleus slices, the drugs shifted muscimol log dose ± response lines to the left in an approximately parallel fashion with the result that 200 mM chlormethiazole potentiated muscimol responses by 0.567+0.037 log unit (mean+s.e.mean, n=4) while loreclezole gave a maximal potentiation at 10 mM of only 0.121+0.037 (n=6) log unit and 0.071+0.039 (n=22) at 50 mM. 3 While 50 mM chlormethiazole and 30 mM pentobarbitone showed no signi®cant interactions between each other when potentiating muscimol responses in combination, 50 mM loreclezole in combination with either chlormethiazole or pentobarbitone attenuated their potentiating eects, possibly by inducing desensitization of GABA A receptors. 4 In the [
Introduction
Much evidence suggests that g-aminobutyric acid A (GABA A ) receptors are the targets of a variety of pharmacologically important drugs, such as benzodiazepines, barbiturates, steroids, general anaesthetics, convulsants acting at the picrotoxin site and chlormethiazole (for review, see Sieghart, 1995) . These classes of drug each act on speci®c binding sites, which can allosterically interact with each other, to modulate the activity of the GABA A receptors. Only for the benzodiazepines (Waord et al., 1994) and barbiturates (Thompson et al., 1996) amongst these drugs is there strong evidence for the modulatory action being dependent on the subunit composition of the receptors.
A more recent addition to the list of GABA A modulators is loreclezole ((Z)-1-(b,2,4-trichlorostyryl)-1H-1,2,4-triazole), a broad spectrum anticonvulsant. It inhibited [
3 H]-phenyl-4-tbutyl-2,6,7-trioxabicyclo(2,2,2)octane (TBOB) binding to the picrotoxin site on GABA A receptors with an IC 50 of 3 mM (Van Rijn & Willems-van Bree, 1993) , behaved more like a barbiturate than a benzodiazepine in two in vivo models (Ashton, et al., 1992) and was not sensitive to the benzodiazepine receptor antagonist,¯umazenil (Dawson et al., 1994) . As a GABA potentiator, loreclezole has been demonstrated to be highly selective for receptors containing the b2 or b3 subunit over those containing the b1 subunit (Waord et al., 1994) , and this unique subunit dependence was determined by a single amino acid, b2 Asn-289 (b3 Asn-290) .
In order to classify the pharmacological mechanism of action of loreclezole, we compared its actions with those of chlormethiazole since there is some structural resemblance between loreclezole and chlormethiazole ( Figure 1 ). We compared these compounds on (a) rat cuneate nucleus slices where chlormethiazole has been shown to potentiate responses to muscimol (Harrison & Simmonds, 1983) and (b) on the modulation of [ 3 H]-¯unitrazepam binding where, unusually for a GABA A potentiator, chlormethiazole did not enhance the binding (Cross et al., 1989) but, at high concentrations, inhibited it (Moody & Skolnick, 1989) . Some further comparisons were also made with pentobarbitone. A preliminary account of a part of this work has been presented (Zhong & Simmonds, 1996) .
In parallel with this work, comparisons between loreclezole, chlormethiazole and pentobarbitone were made on a seizure model and additional ligand-binding sites on the GABA A receptors (Green et al., 1996) .
Methods

Functional study
Experiments were performed on slices of medulla oblongata containing the dorsal funiculus and cuneate nucleus, prepared from male Wistar rats (100 ± 150 g) as previously described (Simmonds, 1978; Harrison & Simmonds, 1983) . Each slice was placed in a two-compartment bath so that the dorsal funiculus projected through a grease-®lled gap in a barrier se-parating the two compartments. The slices were superfused with Krebs medium at room temperature and only the compartment containing the terminals of the dorsal funiculus within the cuneate nucleus was superfused with drugs incorporated into the Krebs medium. The potential dierence between the two compartments was recorded continuously and the negativity induced in the drug-perfused compartment was interpreted as a depolarization of the terminals of dorsal funiculus ®bres projecting through the barrier. Responses were measured at their peak amplitudes.
Muscimol was used routinely as the GABA A receptor agonist. To minimize the problem of desensitization, control responses in the lower part of the log dose-response curve were used and these were routinely obtained from 2 min superfusions of 1.25 and 2.5 mM muscimol. In each experiment, where two drugs were tested both singly and in combination, a muscimol control curve was ®rst obtained, then one drug was superfused for 30 min before and during the redetermination of responses to muscimol. The same procedure was then carried out with a combination of the two drugs. The muscimol dose-response lines were always displaced in an approximately parallel fashion so each experiment gave a single value of the shift of the muscimol log dose-response line by the modulatory drug (see Harrison & Simmonds (1983) for a fuller description).
The Krebs medium contained (mM): NaCl 118, KCl 2.1, KH 2 PO 4 1.2, CaCl 2 2.5, MgSO 4 2.2, NaHCO 3 25 and glucose 11 and was continuously gassed with 95% O 2 : 5% CO 2 to give pH 7.4. Muscimol was prepared as a 10 mM solution in distilled water and diluted into the Krebs medium just before use. Chlormethiazole and pentobarbitone were dissolved directly in the Krebs medium. Loreclezole was ®rst dissolved in a little acetone and then diluted into the Krebs medium. The ®nal concentration of acetone never exceeded 0.1% which had no eect on muscimol responses in this preparation.
Binding study
Membrane preparation Crude rat brain synaptic membranes were prepared as described previously (Prince & Simmonds, 1992) . Brie¯y, male Wistar rats (150 ± 200 g) were killed by decapitation and their brains homogenized in 20 volumes of ice-cold wash buer (5 mM Tris-HCl, 1 mM EDTA, pH 7.4 at 48C) for 1 min, with an Ultra Turrax homogenizer. The homogenate was centrifuged for 10 min at 1000 xg at 48C (Beckman J2 ± 21 M/E centrifuge). The supernatant was collected and centrifuged for 20 min at 48,000 xg. The resultant pellet was resuspended in wash buer and centrifuged for 20 min at 48,000 xg a further three times. The ®nal pellet was resuspended in wash buer at a concentration of 2 ± 3 mg protein ml 71 and then frozen at 7208C until required (14 days maximum). The protein yield was about 20 mg protein g 71 brain.
On the day of the assay, aliquots of 8 ml of stored tissue were thawed and washed twice with 20 ml distilled water and twice with the assay buer (50 mM Tris, 150 mM NaCl, pH 7.4 at 48C) by centrifugation for 20 min at 48,000 xg. The ®nal pellet was resuspended in assay buer to give a protein concentration of approximately 2 mg ml 71 , as determined by the Biorad assay (Biorad Laboratories Ltd).
[
H]-¯unitrazapam (FNZ) binding
Concentration-eect relationship One hundred microlitre aliquots of membranes (0.4 mg protein ml 71 ) were pre-incubated with various concentrations of drugs for 10 min at 378C (Prince & Simmonds, 1992) . Then 50 ml of [ 3 H]-FNZ was added to each tube to give a ®nal concentration of 1 nM and a total volume of 500 ml assay buer. The samples were incubated for 60 min at 48C. The binding reaction was terminated by addition of 2 ml ice-cold wash buer, followed by rapid ®ltration through Whatman GF-C ®lters by use of a Brandel Cell Harvester. The ®lters were washed 4 times with 2 ml ice-cold wash buer and the bound radioactivity quanti®ed by conventional liquid scintillation techniques. Non-speci®c binding, which was less than 5% of the total binding, was determined by addition of 10 mM unlabelled unitrazepam.
Saturation curve One hundred microlitre aliquots of membranes (0.4 mg protein ml 71 ) were incubated with 0.1 ± 20 nM [ 3 H]-FNZ for 60 min at 48C in the presence or absence of loreclezole (100 mM) in a total sample volume of 500 ml. The binding reaction was terminated by the addition of ice-cold wash buer, followed by rapid ®ltration and washing, as described above. Non-speci®c binding, which was less than 5% of the total binding, was determined for each concentration of Loreclezole was initially dissolved in acetone which was present in all samples at a ®nal concentration of 1%. Chlormethiazole and bicuculline ((7)-bicuculline methochloride) were dissolved directly in assay buer. Unlabelled FNZ was initially dissolved in DMSO (dimethyl sulphoxide) or acetone then diluted in assay buer. 71 ) was obtained from Du Pont, U.K. Chlormethiazole and loreclezole were gifts from Astra and Janssen, respectively. Pentobarbitone, muscimol, (7)-bicuculline methochloride, unlabelled FNZ and other chemicals were obtained from Sigma.
Chemicals
Results
Functional study on the cuneate nucleus
Eects of chlormethiazole, pentobarbitone and loreclezole individually The time-courses of the responses to muscimol and the overall appearance of the responses were very similar to those previously described for this preparation (e.g. Simmonds & Turner, 1985) . In agreement with earlier results (Harrison & Simmonds, 1983; Simmonds & Turner, 1987) , chlormethiazole dose-dependently potentiated responses to muscimol on the cuneate nucleus (Figure 2 , P50.0001, one-way ANOVA) and a submaximal concentration of pentobarbitone, 30 mM gave a similar potentiation to 50 mM chlormethiazole. However, loreclezole showed a rather dierent pro®le (Figure 3 ). At 5, 10 and 20 mM, loreclezole gave quite small leftward shifts. At 10 and 20 mM, the shifts were signi®cant (P50.05, P50.01, respectively, Student's t test). At 50 mM, the responses were very variable, ranging from a clear potentiating eect to an antagonizing eect and the mean shift was not signi®cant.
Eect of chlormethiazole, pentobarbitone and loreclezole applied in pairs When pentobarbitone 30 mM was co-applied with chlormethiazole 50 mM, the leftward shifts induced by these two drugs were very similar to the sum of their eects when applied separately (Figure 4) . However, when loreclezole 20 mM and 50 mM were co-applied with pentobarbitone 30 mM, the total shifts were less than the sums of their individual effects. As the concentration of loreclezole increased, the total shift decreased and, with loreclezole 50 mM, was signi®cantly dierent from the predicted sum of the individual eects (P50.05, Student's t test). Similarly, when loreclezole 10 mM and 50 mM were co-applied with chlormethiazole 50 mM, the total shifts were less than the sums of their individual eects and, with loreclezole 50 mM, this dierence was signi®cant (P50.05, Student's t test).
These results suggest that chlormethiazole and pentobarbitone have no interaction between them when potentiating responses to muscimol. However, loreclezole attenuated the eects of chlormethiazole and pentobarbitone. Figure 5 ). The concentration-eect relationship had a threshold at 3 mM and a maximal 47.3+2.83% increase in binding at 300 mM (mean+ s.e.mean, n=3).
In saturation curve analysis, loreclezole 100 mM signi®cantly decreased the K D (P50.01, Student's t test) but not B max of [ presence of chlormethiazole 100 mM, loreclezole gave signi®-cantly smaller enhancements (Figure 7) , the decreases being signi®cant (P50.05, Student's t test) with loreclezole 100 mM, 300 mM and 1 mM. These results suggest that chlormethiazole can partially block the potentiating eect of loreclezole on [ 3 H]-FNZ binding.
Eect of bicuculline on the enhancement by loreclezole of [
3 H]-FNZ binding On well washed membranes, there was very little endogenous GABA left, as evidenced by the fact that 100 mM bicuculline failed to reduce [ 3 H]-FNZ binding signi®-cantly (73.9+1.96% from control, mean+s.e.mean, n=3). Nevertheless, it was possible that part of the potentiating action of loreclezole on [ 3 H]-FNZ binding was due to potentiation of a subthreshold GABA tone. Therefore, in this series of experiments, 100 mM bicuculline was routinely used.
The in¯uence of 100 mM bicuculline on the concentration ± eect relationship for 60 min exposure to loreclezole is shown in Figure 7 . In the presence of bicuculline 100 mM loreclezole gave a smaller enhancement of [ 3 H]-FNZ binding than in the absence of bicuculline, the decreases with 30 mM, 300 mM and 1 mM loreclezole being signi®cant (P50.05, Student's t test). These results suggest that there are bicuculline-sensitive and bicucullin-insensitive components in the enhancement by loreclezole of [
3 H]-FNZ binding.
Eect of bicuculline and chlormethiazole on the enhancement by loreclezole of [ 3 H]-FNZ binding Since the concentration ± eect relationships of loreclezole in the presence of chlormethiazole or bicuculline were superimposed on each other, we were interested to ®nd out if the two components identi®ed by chlormethiazole and bicuculline were the same. A combination of 100 mM chlormethiazole and 100 mM bicuculline did not depress the enhancement by loreclezole of [ 
Discussion
Compared to chlormethiazole and pentobarbitone, loreclezole generated much smaller potentiations of muscimol responses in the cuneate nucleus. At high concentrations (50 mM), loreclezole induced very variable responses, ranging from a clear potentiating eect to an antagonizing eect. When 50 mM loreclezole was co-applied with pentobarbitone or chlormethiazole, it attenuated the eects of chlormethiazole and pentobarbitone. One explanation could be that loreclezole acted on the same site as chlormethiazole and pentobarbitone and acted as a partial agonist to antagonize their potentiating effects. However, the fact that chlormethiazole and pentobarbitone had no interaction between themselves when potentiating responses to GABA suggests that chlormethiazole and pentobarbitone do not share common binding sites. The most plausible explanation of the attenuations by loreclezole of the actions of chlormethiazole and pentobarbitone, and the variable responses induced by loreclezole on its own, is that loreclezole not only potentiates the muscimol responses but also induces desensitization of GABA A receptors. Direct evidence in support of this explanation has come from a recent study (Donnelly & Macdonald, 1996) , in which it was clearly shown that loreclezole increases desensitization of GABA A receptor-mediated responses to GABA recorded intracellularly. In the present experiments, therefore, it seems likely that the muscimol-potentiating eect of loreclezole was largely obscured by a concomitant exacerbation of desensitization.
Loreclezole considerably enhanced [ 3 H]-FNZ binding to the crude synaptic membranes prepared from rat whole brain homogenate and this enhancement was due to an increase in binding anity rather than a change in the number of binding sites. Both chlormethiazole and bicuculline could block the enhancement by loreclezole of [ 3 H]-FNZ binding to a small extent. The combination of them failed to depress the enhancement by loreclezole any further than either chlormethiazole or bicuculline on its own. This suggests that the component that is sensitive to chlormethiazole is also sensitive to bicuculline and therefore GABA-dependent, and the remaining component is a direct eect of loreclezole which is neither dependent on GABA nor in¯uenced by chlormethiazole. An analogous, bicuculline-resistant enhancement by loreclezole of the binding of the picrotoxin site ligand [ 35 S]-TBPS has been found (Sanna et al., 1996) Moody & Skolnick (1989) , but not with those of Cross et al. (1989) . Bicuculline similarly did not reduce this eect of pentobarbitone. These observations further support the contention that, under the conditions of our [
3 H]-FNZ binding experiments on well-washed whole brain membranes, with only low levels of endogenous GABA likely to have been present, it was predominantly the direct actions of drugs on the GABA A receptor that were seen.
In this study, the data on potentiation of muscimol responses were obtained on tissue from a lower level of the neuraxis than the tissue on which [
3 H]-FNZ binding was studied. It is conceivable, therefore, that the spectrum of subunit compositions of the GABA A receptors diered between these two preparations. We do not know to what extent, if at all, this may have contributed to the dierent patterns of modulation of muscimol responses and [
3 H]-FNZ binding. A further complication is the suggestion that loreclezole has two distinct sites of action on the GABA A receptor; a b2/3 subunit-speci®c site for potentiation of GABA and a site for desensitization that does not depend on the type of b-subunit present (Donnelly & Macdonald, 1996) . In view of the dominant in¯uence of desensitization in our cuneate nucleus experiments, it is dicult to draw a ®rm conclusion on the question of a common site for the GABA-potentiating actions of loreclezole and chlormethiazole.
